EBRD invests in the rapidly growing Turkish tech company, obilet.com
European Bank for Reconstruction and Development (EBRD) invested in obilet.com, the online sales platform for users to purchase bus and airline tickets. EBRD, which offers financing for thousands of projects to support local growth in European countries, has invested $11 billion in Turkish businesses and projects to date. Earlybird Venture Capital, an investor in obilet.com, announced that it will also participate in the next round of funding.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191212005302/en/
EBRD added obilet.com, Turkey's fastest-growing online ticket sales platform, to its investment portfolio. Yigit Gurocak, (obilet.com CEO and Co-founder) and Ali Yılmaz, (obilet.com Co-founder) (Photo: Business Wire)
Yigit Gurocak, CEO - obilet.com, said that the company aimed to provide services to different segments of the transportation industry by expanding its teams in 2020 with the support of new investments.
The company, currently at 400 million visitors, aims to sell 18 million tickets in 2020!
obilet.com, which offers comparison and purchasing options for bus and airline tickets of more than 150 bus operators and 1000 airlines, was founded in 2012 by two university students and entrepreneurs, Ali Yilmaz and Yigit Gurocak. The company’s CEO Yigit Gurocak summarized the last seven years, “Starting from its inception to the present day, obilet.com recorded outstanding growth to reach 400 million visitors, now ranks the top-visited travel site in Turkey.”
The initiative of two entrepreneurs’ dreams, obilet.com currently operates with 160 employees and is expected to maintain its growth in the Turkish travel industry, which reportedly has a size of approximately $15 billion. Yigit Gurocak said that the company aims to sell 18 million tickets in 2020 on obilet.com and the mobile app in Turkey, where 300 million tickets are sold in total.
The Turkish startup to receive highest international funding
According to Startups Watch data, obilet.com stood out as the Turkish startup to receive the highest amount of international funding in 2018 Q2 and when the investment was acquired in November 2019, it was the largest amount of investment of 2019 up until that point. With the participation of EBRD in the latest round, obilet.com has received its fourth investment round in the last five years leading the Turkish technology and travel sectors in this aspect. With this investment, obilet.com raised $10 million within one year.
Named “Europe's Best Travel App” by Mastercard in 2015, obilet.com ranked eighth among the fastest-growing companies listed in the 2017 Deloitte Technology Fast 50 program with a growth rate of 1041%. Most recently, obilet.com was also listed among Turkey’s 100 Fastest Growing Businesses according to the results of a 2019 survey conducted by the Union of Chambers and Commodity Exchanges of Turkey (TOBB) and the Economic Policy Research Foundation of Turkey (TEPAV).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005302/en/
Contact information
Contact Details:
Sena Ozkurt
sena@obilet.com
+905348960414
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom